Acute renal failure and sepsis N Engl J Med 2004;351:159–69 Pub

Acute renal failure and sepsis. N Engl J Med. 2004;351:159–69.PubMedCrossRef 13. Piccinni P, Cruz DN, Gramaticopolo S, et al. Ralimetinib in vitro Prospective multicenter study on epidemiology of acute kidney injury in the ICU: a critical care nephrology Italian collaborative effort (NEFROINT). Minerva Anestesiol. 2011;77:1072–83.PubMed find more 14. Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc. 1999;74:519–28.PubMed 15. Armendariz E, Chelluri L, Ptachcinski R. Pharmacokinetics of amikacin during continuous veno-venous hemofiltration. Crit Care Med. 1990;18:675–6.PubMedCrossRef 16. Cotera A, Aguila R, Gaete L, Saffie A, Lorca E, Thambo S. Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis.

Rev Med Chil. 1995;123:742–8.PubMed 17. Joos B, Schmidli M, Keusch G. Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration. Nephrol Dial Transplant. 1996;11:1582–5.PubMedCrossRef 18. Robert R, Rochard E, Malin F, Bouquet S. Amikacin pharmacokinetics during continuous veno-venous hemofiltration. Crit Care Med. 1991;19:588–9.PubMedCrossRef Selleck LDK378 19. Taccone FS, de Backer D, Laterre PF, et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents. 2011;37:531–5.PubMedCrossRef 20. Akers KS, Cota JM, Frei CR, et al. Once-daily amikacin dosing in burn

patients treated with continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2011;55:4639–42.PubMedCentralPubMedCrossRef 21. D’Arcy DM, Casey Oxymatrine E, Gowing CM, Donnelly MB, Corrigan OI. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration. BMC Pharmacol Toxicol. 2012;13:14.PubMedCentralPubMedCrossRef 22. Yamamoto T, Yasuno N, Katada S, et al. Proposal of a pharmacokinetically optimized

dosage regimen of antibiotics in patients receiving continuous hemodiafiltration. Antimicrob Agents Chemother. 2011;55:5804–12.PubMedCentralPubMedCrossRef 23. Ricci Z, Ronco C, D’Amico G, et al. Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. Nephrol Dial Transplant. 2006;21:690–6.PubMedCrossRef 24. Bertrand X, Dowzicky MJ. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the tigecycline evaluation and surveillance trial. Clin Ther. 2012;34:124–37.PubMedCrossRef 25. Taccone FS, Laterre PF, Spapen H, et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010;14:R53.PubMedCentralPubMedCrossRef 26. Golper TA, Wedel SK, Kaplan AA, et al. Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Int J Artif Organs. 1985;8:307–12.PubMed 27.

Comments are closed.